TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04402788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06398951

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Two nare high flow nasal cannula
Description: Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two nare high flow nasal cannula
Description: Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
Study: NCT06067750

Intervention type: DIAGNOSTIC_TEST
Intervention: Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)
Description: All patients will receive Narcotrend and CFAM monitoring in this observational study
Study: NCT04402788

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT06117904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO ointment
Description: This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment only
Description: This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment only
Description: This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets).
Study: NCT05480761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sucraid (sacrosidase) Oral Solution 8500 IU/mL
Description: Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
Study: NCT06344130

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.
Study: NCT05197309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Diet
Description: Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Diet
Description: Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
Study: NCT04705350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zampilimab
Description: Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
Study: NCT06118515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir is a novel inhibitor targeting the cytomegalovirus (CMV) viral enzyme, effectively disrupting the production of additional CMV virions. Letermovir has demonstrated potent, selective, and reversible inhibition of CMV activity in preclinical studies.
Study: NCT05468619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir is a L-valyl ester of acyclovir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir is a L-valyl ester of acyclovir.
Study: NCT04824105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
Study: NCT04705350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo at a pre-specified time point to maintain the blinding.
Study: NCT04822441

Intervention type: OTHER
Intervention: data collection
Description: Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord

Intervention type: OTHER
Intervention: data collection
Description: Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord

Intervention type: OTHER
Intervention: data collection
Description: Ultrasound follow-up maternal dengue serology PCR (Polymerase Chain Reaction) and dengue serology of the umbilical cord
Study: NCT06305091

Intervention type: DIAGNOSTIC_TEST
Intervention: Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
Description: Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
Description: Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
Study: NCT05637957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation
Description: Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
Study: NCT04804904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: TQ-B3101 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: TQ-B3101 oral capsule
Study: NCT04826029

Intervention type: OTHER
Group type: OTHER
Intervention: Standard strategy
Description: In the standard arm, patients will complete CA 125 (+/- HE4) at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days), complete the HAD and EQ5D self-questionnaires, and be managed according to INCa 2018 recommendations. If clinical symptoms, marker elevation, and/or imaging workup occur, the patient will be referred to the multidisciplinary consultation meeting (MDC) for management according to INCa 2018.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up strategy
Description: In the interventional arm, patients will perform at 3 months, 6 months, 12 months, 18 months and 24 months (+/- 15 days) a CA125 assay (+/- HE4 assay), a thoracoabdominal CT scan after contrast injection and a whole body MRI (T2, DW and T1 sequences after fat saturation before and after gadolinium injection) with a maximum delay of 15 days between the two examinations, and will complete the HAD and EQ5D self-questionnaires. A senior radiologist from each center will perform a prospective reading of each of the images. For any suspicious anomaly identified, the following criteria will be analyzed: Size, location, number, evolution, contrast after injection, MRI signal (T2, Diffusion, Dynamic Enhancement Curve). The RECIST criteria (version 1.1) will be applied.
Study: NCT05703113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web 2.0 tools
Description: Education with Web 2.0 tools
Study: NCT04781049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Perineal Laser Ablation of Prostate
Description: TPLA treatment will be performed using the EchoLaser EVO system (Elesta SpA - Calenzano, FI, Italy). EchoLaser EVO consists of four echolasers, a multi-source laser system with a wavelength of 1064nm and Echolaser Smart Interface (ESI), a treatment planning device for safely inserting introductor needles and optical fibers into prostate tissue. EchoLaser therapy is a micro-invasive percutaneous procedure that uses laser light transmitted through applicators (optical fibers) for a few minutes, causing a heating of the affected tissue to its irreversible damage in situ, without the need to remove it. EchoLaser therapy, through flat-tip fibers, produces an ellipsoidal clotting area (area where the tissue has irreversible damage). EchoLaser therapy will be performed under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-Urethral Resection of Prostate
Description: TURP is the gold standard for the treatment of benign prostatic obstruction. It will be performed by using a bipolar energy resectoscope. The procedure will be carried out with patient in a lithotomic position.
Study: NCT04791423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRAd-COV2
Description: GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT04573764

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester
Description: The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste-matched water
Study: NCT05973266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application-Based Bowel Preparation Training
Description: The contents of the training in the mobile application where the patients receive bowel preparation training before the procedure are; short videos, images and slides about colonoscopy, bowel preparation drugs, liquid-clear diet and foods recommendations.A mobile application-based training will be provided to guide patients, where user (patient) usage activities are monitored by the researcher, sending notifications or reminders to the patient in accordance with the colonoscopy procedure date.
Study: NCT04719962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted proteomics in skin +/- cerebrospinal or synovial fluid to diagnose disseminated Lyme disease
Description: Following a 2-days course of local daily clobetasol propionate 0,05% cream application, a skin biopsy (3 mm punch-biopsy ) of healthy-looking skin of the upper part of the thigh will be performed in all patients,.~Arthrocentesis (in patients with Lyme arthritis only) and lumbar puncture to collect cerebrospinal fluid (in patients with neuroborreliosis only) will be performed in the usual care setting as appropriated.~All biological samples will be subject to Borrelia culture, PCR and SRM-MS proteomics.
Study: NCT05515692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo radiotherapy simulation using CT

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electron Beam Therapy
Description: Undergo electron beam radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Frequency Ultrasound Imaging
Description: Undergo HFUS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo radiotherapy simulation using clinical setup

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: Undergo biopsy
Study: NCT05016895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Description: Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
Study: NCT05225532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of ganglionated plexi located in the left or right atrium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of ganglionated plexi located in the left or right atrium
Study: NCT05519215

Intervention type: DEVICE
Intervention: ECHELON 3000 Stapler
Description: There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
Study: NCT06101316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB06-036
Description: CB06-036 Capsule
Study: NCT06011213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Issuing health risk warning for a heat waves or cold spells
Description: Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital heat or cold health risk early warning tool
Description: A WeChat mini-program provides real-time updates on early warnings and health advisories.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure and ECG device
Description: Devices for self-monitoring blood pressure and ECG

Intervention type: DEVICE
Group type: OTHER
Intervention: Self-monitoring blood pressure and ECG device
Description: Devices for self-monitoring blood pressure and ECG

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perform daily self-monitoring of their BP and ECG
Description: Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perform daily self-monitoring of their BP and ECG
Description: Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
Study: NCT04986423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: 72 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: 72 mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg PO QD
Study: NCT06083285

Intervention type: OTHER
Intervention: Implement the CRRT specialist nursing group management program on the basis of routine care
Description: Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
Study: NCT06279091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: apply breathing exercises to evaluate the effectiveness on anxiety reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bubble Blower Breathing
Description: apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell Show Do
Description: apply basic behavioral management technique as control group
Study: NCT04394260

Intervention type: BEHAVIORAL
Intervention: Savvy Caregiver Program via Remote Learning
Description: The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
Study: NCT04899869

Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation with active study microbiota first
Description: 2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota

Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation with inactive autoclaved study microbiota first
Description: 2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota

Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation with inactive autoclaved study microbiota only
Description: 2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
Study: NCT05466877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10
Description: MG-K10 Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10
Description: MG-K10 Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-K10
Description: MG-K10 Humanized Monoclonal Antibody Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MG-K10 Humanized Monoclonal Antibody Injection